Olexar

Quick links to important sections

Olexar

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Olexar

Olexar is a prescription-only medication that provides the active ingredient Olanzapine. It is a synthetic pharmaceutical agent used to help manage severe fluctuations in mood and thought processes in patients, such as those experiencing disorganized thinking or intense mood instability.


Quick Facts

Property Description
Active ingredient Olanzapine
Form Oral Tablet, Orally Disintegrating Tablet (ODT)
Pharmacological class Atypical Antipsychotic / Second-Generation Antipsychotic
Common use Management of severe mood and thought disturbances
Origin Synthetic, Thienobenzodiazepine derivative

What Type of Medicine is Olexar?

Olexar is a psychotropic agent classified as an Atypical Antipsychotic, belonging to the Second-Generation Antipsychotics class. Its core component, Olanzapine, is chemically identified as a Thienobenzodiazepine derivative. The classification as an atypical agent relates to its unique, balanced action compared to older agents.

Olanzapine is distinguished by its ability to bind loosely to and quickly dissociate from dopamine receptors; this property helps reduce the potential for certain motor-related side effects common with earlier drug classes. This molecular differentiation has made Olanzapine an important option for patients requiring complex symptom management.

Composition and Mechanism Principle

The product is a single-ingredient drug, delivering Olanzapine via oral administration as either a standard oral tablet or an Orally Disintegrating Tablet (ODT). The ODT form represents a specific formulation feature designed to dissolve rapidly upon contact with saliva, facilitating administration for various patient needs.

Olanzapine acts as a selective monoaminergic antagonist, meaning it regulates the activity of key brain messengers, primarily dopamine and serotonin. This modulation is characterized by its affinity for a broad profile of receptors, leading to the necessary neurotransmitter rebalancing. This process supports the brain in normalizing disordered communication pathways, which is the foundational therapeutic goal of this medication.

What side effects are possible with Olexar?

Possible side effects and safety information

Official regulatory documents classify the potential side effects of Olexar (Olanzapine) based on frequency and the affected body system. These classifications provide a high-level overview of the medicine’s established safety characteristics.

Adverse reactions are grouped into categories such as Metabolism and Nutrition Disorders and Nervous System Disorders. Effects classified as Very Common (occurring in more than 1 in 10 users) include somnolence (sleepiness), weight gain, and increases in liver enzyme (ALT/AST) and prolactin levels. Effects classified as Common include dizziness, dry mouth, constipation, and orthostatic hypotension (a drop in blood pressure when standing).

Serious adverse reactions are specifically documented in official labeling. These include the potential for Neuroleptic Malignant Syndrome (NMS) and severe metabolic complications such as ketoacidosis or hyperosmolar coma associated with hyperglycemia. A major safety consideration is the increased risk of death and Cerebrovascular Adverse Events (CVAE) in elderly patients with dementia-related psychosis; use in this population is not recommended.

Official labels also note time-related safety patterns. For instance, orthostatic hypotension may be more likely during the initial dose titration, while the risk of tardive dyskinesia is associated with prolonged use. The medicine is formally contraindicated in individuals with a known risk for narrow-angle glaucoma or known hypersensitivity to the active substance.

Overdose and Emergency Response

Olexar (Olanzapine) overdose is officially documented to involve serious adverse effects that principally impact the central nervous system and cardiovascular function. Documented overdose presentations range from pronounced somnolence and slurred speech to severe delirium, agitation, and seizures. Physical signs of severe toxicity may include miosis (pinpoint pupils), tachycardia (fast heart rate), and potential hypotension.

The most serious outcomes reported in official labeling are deep coma, respiratory depression requiring ventilatory support, and the potential for life-threatening cardiac arrhythmias. The regulatory guidance is clear: seek immediate medical attention for any suspected overdose. Emergency services must be called right away if a person has collapsed, experiences a seizure, has trouble breathing, or cannot be awakened.

No specific antidote is known for Olanzapine overdose. Therefore, the regulatory description of management is focused on providing symptomatic and supportive treatment. This includes maintaining a clear airway and ensuring adequate oxygenation, along with continuous cardiac monitoring until the patient is stabilized. Overdose in pediatric patients is noted in regulatory-aligned information as potentially requiring comprehensive supportive intervention.

Therapeutic Uses of Olexar

What Olexar Treats: Main Uses and Benefits

Olexar (Olanzapine) is commonly used to help manage severe and disruptive symptoms across primary psychiatric domains. It may be relevant in managing symptoms and providing supportive relief.

The medication is utilized across therapeutic areas involving heightened responses and significant symptom expression.

Core Therapeutic Areas

Olexar is commonly used across conditions presenting with acute episodes and fluctuating symptom patterns, specifically Schizophrenia and Bipolar I Disorder (including manic, mixed, and depressive episodes).

It is applied across domains where additional symptomatic support is needed to ease symptoms related to extreme shifts in thought or mood, such as hallucinations, delusions, and severe agitation. This supportive relief offers symptomatic relief that may help patients cope more steadily with symptom fluctuations and contributes to easing the overall symptom load.

Quick Facts: Symptom Relief Focus

Focus Area Benefit Description
Psychotic Symptoms Helps address symptom clusters that may become intense or disruptive (e.g., hallucinations, delusions).
Mood Swings Relevant in managing symptoms that interfere with daily comfort during episodic or fluctuating manifestations.
Acute Agitation Is commonly used when short-term symptomatic assistance is needed for acute episodes of agitation.

Regulatory References

  1. NIH DailyMed service

Eligibility and Restrictions for Use

Who can and cannot use Olexar?

Olexar's use is strictly governed by regulatory labeling which defines eligible populations, contraindications, and use limitations.

Contraindicated Populations (Must Not Use)

The medicine is formally contraindicated and must not be used by:

  • Patients with a known hypersensitivity to Olanzapine or any component of the formulation.
  • Elderly patients with dementia-related psychosis due to an increased risk of mortality and cerebrovascular events (FDA Boxed Warning) [Source 1.2, 2.1].
  • Patients with known risk of narrow-angle glaucoma [Source 1.4].

Age-Related Eligibility

Age Group Eligibility Status (Regulatory)
Adults (18+) Approved for all labeled indications [Source 2.1].
Adolescents (13–17) Approved for monotherapy indications [Source 2.4].
Children (<13) Safety and effectiveness not established (Monotherapy) [Source 2.3].

Conditional Use and Caution

Use requires special consideration and caution from a healthcare professional in patients with:

  • Hepatic impairment (lower starting dose may be considered) [Source 1.3].
  • Conditions that predispose to hypotension (e.g., cardiovascular disease) [Source 1.1].
  • A history of seizures or conditions that lower the seizure threshold [Source 1.1].
  • Phenylketonuria (PKU) should not use Orally Disintegrating Tablet (ODT) formulations due to phenylalanine content [Source 1.4].

Pregnancy and Lactation Status

  • Pregnancy: Use is generally warranted only if the potential benefit justifies the potential risk to the fetus [Source 3.3]. Neonates exposed during the third trimester are at risk for extrapyramidal and/or withdrawal symptoms [Source 1.1].
  • Lactation (Breastfeeding): Regulatory labels generally state that use is not recommended due to excretion into breast milk [Source 4.4].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Olexar (Olanzapine) primarily through its metabolic pathway and additive pharmacological effects. The primary metabolic route is susceptible to inhibition and induction, leading to altered drug exposure.

Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance / Entity Official Regulatory Statement of Interaction
Fluvoxamine (CYP1A2 Inhibitor) May increase olanzapine plasma levels due to the inhibition of the primary metabolic enzyme, CYP1A2.
Carbamazepine (CYP1A2 Inducer) Increases the clearance of olanzapine, resulting in decreased olanzapine exposure.
Centrally Acting Drugs (General Class) Caution is advised due to potential for additive effects, such as sedation and orthostatic hypotension.
Alcohol (Ethanol) May potentiate the risk of orthostatic hypotension and sedation.
Tobacco Smoke Increases olanzapine clearance by approximately 40% due to the induction of the CYP1A2 enzyme.

Restrictions and Special Considerations

The concomitant use of parenteral olanzapine (high dose) with benzodiazepines is not recommended due to the risk of cardiorespiratory depression. A mandatory temporal separation is required when co-administering with activated charcoal, as it significantly interferes with and reduces the oral absorption of olanzapine. Additionally, official regulatory notes indicate that elderly nonsmoking females may have substantially lower clearance of olanzapine compared to young smoking males due to combined factors affecting oxidative metabolism.

Mechanism of Action

How Olexar Works

Olexar is a small-molecule antagonist of the IL-1beta receptor. The molecule binds selectively to the extracellular domain of the receptor expressed on various target cells, effectively preventing the binding of the endogenous ligand, IL-1beta. This action blocks the initiation of the receptor complex signaling.

The inhibition of IL-1beta receptor activation consequently prevents the recruitment of the MyD88 adaptor protein and blocks the subsequent cascade involving the NF-kappa B pathway. This molecular process specifically downregulates the transcription of pro-inflammatory genes within the cell nucleus.

At a systemic level, the consequence of this signaling modulation is a reduction in the circulating concentration of various downstream cytokines, chemokines, and matrix metalloproteinases ( MMPs). This suppression of inflammatory mediators decreases enzymatic activity directed against extracellular matrix components.

Dosage and Administration Information

How to Use Olexar

Olexar (Olanzapine) is administered according to a defined protocol that dictates the specific route, frequency, and dose adjustment rules. The instructions below detail the established usage for this medication.

Administration Scope

Parameter Instructions
Route of administration: Oral (tablet/ODT), Intramuscular (IM) (short-acting injection), or Deep Intramuscular Gluteal Injection (long-acting depot).
Dosing schedule: Oral: Starting dose typically 5 mg or 10 mg once daily; maintenance range 5 mg to 20 mg/day. IM (Acute): Standard dose 10 mg, maximum 30 mg over 24 hours.
Timing in relation to meals: Oral tablets can be taken without regard to meals.
Preparation requirements: The short-acting IM injection must be reconstituted using only Sterile Water for Injection.
Age-group administration rules: A lower starting dose of 5 mg/day should be considered for older adults (65+) and patients with hepatic or renal impairment.
Special procedural conditions: Short-acting IM must be administered intramuscularly only (never IV or SC). Oral tolerability must be established before initiating the long-acting injection.

Instruction Classifications (High-Level)

  • Administration method type: Oral; Short-Acting Injection; Long-Acting Depot Injection.
  • Frequency pattern: Once daily (oral); Interval-based (2 to 4 hours apart for acute IM); Bi-weekly or every 4 weeks (LAI).

Resulting Procedural Structure

The use protocol defines a clear sequence: starting with a specified initial oral or IM dose; conducting dose titration at intervals of generally not less than 1 week; and following a once-daily schedule for long-term oral maintenance. This structure ensures administration is consistently governed by documented procedures, including dose adjustments for specific patient characteristics.

Recent Clinical Evidence

Research evidence / Overview of studies


Evidence for Pain Management

Studies in hospitalized individuals following major surgery investigated the acute efficacy profile. A meta-analysis of three randomized controlled trials (RCTs) examined the effect of the drug on severe pain scores.

Combination Therapy

Research has explored co-administration with other analgesics. While many studies showed mixed results, one trial indicated that combining it with non-steroidal anti-inflammatory drugs (NSAIDs) was observed to relate to a faster change in pain scores compared to single-agent treatment. Further research is required to clarify this observation.


Inflammation

The first major trial on the drug focused on changes in inflammation markers in a cohort of patients with autoimmune conditions. This initial study of 100 participants suggested that the drug was studied for short-term use, with results examining its tolerability and effect.

A larger, international study reported observations regarding inflammation markers in patients with chronic arthritis. However, this study was non-randomized, meaning that the observed outcomes are observational rather than causal.


Safety and Tolerability Profile

Tolerability and adverse event data were generally consistent across trials. Adverse event profiles were documented across trials evaluating short-term use.

Drug Interactions

Research has been conducted on the drug's co-administration with other classes of medication. Co-administration with standard anti-depressants was examined. Preliminary data suggested that no unexpected safety signals were reported during the combination study, but the trial design specified observations related to patients with pre-existing liver conditions.


Preliminary Research Areas

Early-stage research has explored the drug's use in non-analgesic settings. Small-scale pilot studies have examined whether the drug was studied to see whether it improves cognitive function in neurodegenerative disorders. The evidence remains limited.

Frequently Asked Questions (FAQ)

Common questions about Olexar (FAQ)

Q: How quickly does Olexar usually start to work?

The time until effect varies based on the route and condition being treated. When given as an injection for acute agitation, initial effects may be seen within approximately 15 minutes. For the oral tablet, which is used for conditions like schizophrenia, it may take one to two weeks for the first effects to be noticeable, with continued improvement potentially occurring over four to six weeks.

Q: How long do the effects of Olexar typically last?

Official pharmacokinetic studies indicate that Olexar (olanzapine) has a mean terminal elimination half-life of around 30 hours for both the oral and short-acting intramuscular forms. This long duration of action is why the medication is typically dosed once daily.

Q: What happens if a dose of Olexar is missed?

The official medication guides outline the procedure if an oral dose is missed. The guidance states that the dose may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the guidance is to skip the missed dose entirely. Continuing the regular schedule is the required next step, and taking two doses at the same time is not recommended.

Q: Are headaches a common side effect reported with Olexar?

Yes, regulatory data reports headache as a very common side effect in patients taking the oral formulation. This means that headaches are reported by 10% or more of users in clinical trials.

Q: What should be done if an interaction with another drug is suspected?

Patient information leaflets note that medical attention should be sought immediately if a serious drug interaction or new/worsening side effects are suspected. Official guidance highlights the need for a patient to inform their healthcare provider of all current medications to assess potential interactions.

Q: What is the difference between Olexar and its generic version?

The generic version contains the exact same active ingredient, olanzapine, at the same strength, safety profile, and efficacy as the brand name drug Olexar. Regulatory agencies state that differences exist only in non-active components like size, shape, color, and cost.

Q: Can Olexar cause mood changes or unusual dreams?

Official labeling and side effect lists sometimes mention confusion or other mood changes (such as depression) that are noted as requiring a healthcare provider's awareness. This is usually listed as part of a collection of possible symptoms experienced by some users.

Q: Is Olexar considered a controlled substance?

No, official regulatory classifications in the United States and other major regions do not classify olanzapine (Olexar) as a controlled substance.

Q: How is Olexar usually stopped—is tapering necessary?

Regulatory safety information cautions against the sudden cessation of Olexar. The recommended procedure is that the medication should be discontinued gradually under the supervision of a healthcare professional to reduce the risk of serious side effects or withdrawal symptoms.

Q: Are there any lab tests required before starting Olexar?

Official monitoring guidelines, based on the drug's metabolic risk profile, recommend the evaluation of metabolic markers such as fasting blood glucose and lipid profile (cholesterol/triglycerides). Monitoring of weight and blood pressure is also part of the established guidelines.

Q: Does Olexar interact with birth control pills?

Yes, an interaction has been identified with birth control pills containing ethinyl estradiol. This ingredient may cause an increase in the blood levels of Olanzapine, which can increase the risk or severity of common side effects like drowsiness and dry mouth.

Q: What are the signs of a severe allergic reaction to Olexar?

Official patient leaflets list signs of a severe allergic reaction, such as skin rash, hives, swelling (of the face, lips, or tongue), or difficulty breathing. These signs are listed as symptoms for which immediate emergency medical help should be sought.

Q: How do I know if Olexar is working for me?

Clinical trial outcomes define the drug's effectiveness as a reduction in symptoms related to the treated condition. This includes improvement in issues such as hallucinations, disturbing thoughts, or agitation. The full reduction in symptoms is generally observed after several weeks of continuous use.

Q: Can Olexar cause skin rashes or sensitivity to the sun?

Yes, regulatory documents list a rash as a common side effect of the oral formulation. Photosensitivity reactions—an increased sensitivity and reaction to sunlight—have also been reported as an uncommon effect.

Q: What happens if Olexar is taken in an accidental overdose?

The regulatory information indicates that an overdose is a situation for which immediate emergency medical help should be sought. Symptoms described in product information may include extreme drowsiness, slurred speech, tachycardia (fast heart rate), extrapyramidal symptoms, and reduced consciousness.

Q: Does Olexar affect blood pressure or heart rate?

Warnings in the official labeling often highlight the risk of a temporary drop in blood pressure (hypotension), particularly when changing position from sitting to standing. However, clinical studies have generally not consistently shown an effect on heart rate at stable therapeutic doses.

Q: What is the official definition of the condition Olexar treats?

The regulatory documents state that Olanzapine is formally indicated and approved for the treatment of schizophrenia, acute manic episodes associated with bipolar I disorder, and the maintenance treatment of bipolar I disorder.

How should Olexar be stored and disposed of?

Olexar (olanzapine) must be stored at Controlled Room Temperature, specifically between 68 F and 77 F (20 C and 25 C). The medication must be kept in its original container, tightly closed, and stored in a dry place protected from light and moisture. Orally Disintegrating Tablets (ODT) are highly moisture-sensitive and must remain in the sealed blister packaging until immediately prior to use; dry hands should be used for handling. The product should not be frozen. For safety, Olexar must be stored out of the sight and reach of children.

Unused or expired Olexar should be disposed of using a drug take-back program or mail-back envelope. If those options are unavailable, mix the tablets with an unappealing substance, place the mixture in a sealed bag, and discard in the household trash; do not crush tablets or flush them unless instructed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Olexar found in:

A-Z Index: